Dermatology Advisor

Pediatric Dupilumab Use Linked to Increased Ocular Surface Disease Risk

Dupilumab use in children appears to be tied to a higher incidence of inflammatory eye conditions, including conjunctivitis ...
Healio

Most dupilumab use for asthma, CRSwNP categorized as persistent

Please provide your email address to receive an email when new articles are posted on . 25% of patients experienced a gap of 60 days or more since they last filled their prescription. Patients with ...
Medscape

Dupilumab Use Tied to Autoimmune Skin Disease Risk in Kids

Researchers analyzed data of 178,977 children with atopic dermatitis and/or persistent asthma (median age, 11.8 years; 47.2% girls) from PEDSnet, a pediatric clinical research network in the US, to ...
The American Journal of Managed Care

Dupilumab Efficacy, Reduced Corticosteroid Use in Children With Moderate to Severe Asthma

Posters presented at ACAAI 2023 Annual Scientific Congress examined dupilumab use in children with moderate-to-severe asthma and in the presence of elevated type 2 biomarkers. Two posters presented at ...
Medscape

Dupilumab for Eosinophilic Esophagitis: How Is it Improving Treatment?

The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the safety and efficacy of the drug, which ...
Healio

Dupilumab associated with significantly lower malignancy risks in atopic dermatitis

Please provide your email address to receive an email when new articles are posted on . Researchers compared dupilumab use with other and with no systemic therapy. Dupilumab inhibits IL-4 and IL-13, ...

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...
The American Journal of Managed Care

Dupilumab Considered Safe, Effective for AD in Real-Life Settings

This study enhances current understandings of dupilumab use in patients with atopic dermatitis (AD) by showing its real-world effectiveness and safety. Dupilumab is an effective and safe treatment ...
Dermatology Advisor

Proactive Intermittent Tacrolimus Use After Dupilumab Reduces Flare Risk in AD

Intermittent tacrolimus after dupilumab discontinuation in patients with AD was associated with longer time to disease flare than on-demand therapy.
European Medical Journal

Dupilumab Significantly Reduces Disease Severity in Prurigo Nodularis

Dupilumab shows significant benefits in prurigo nodularis severity and healing outcomes. Learn more about the latest Phase III trial findings.
Monthly Prescribing Reference

Dupilumab Looks Promising for Patients With Bullous Pemphigoid

Findings showed 20% of patients treated with dupilumab experienced sustained disease remission at week 36 compared with 4% of those who received placebo. Treatment with dupilumab led to significant ...
Nasdaq

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...